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There is public concern that use of mobile phones could increase the risk of brain tumours. If such an effect exists, acoustic neuroma
would be of particular concern because of the proximity of the acoustic nerve to the handset. We conducted, to a shared protocol,
six population-based case–control studies in four Nordic countries and the UK to assess the risk of acoustic neuroma in relation to
mobile phone use. Data were collected by personal interview from 678 cases of acoustic neuroma and 3553 controls. The risk of
acoustic neuroma in relation to regular mobile phone use in the pooled data set was not raised (odds ratio (OR)¼0.9, 95%
confidence interval (CI): 0.7–1.1). There was no association of risk with duration of use, lifetime cumulative hours of use or number
of calls, for phone use overall or for analogue or digital phones separately. Risk of a tumour on the same side of the head as reported
phone use was raised for use for 10 years or longer (OR¼1.8, 95% CI: 1.1–3.1). The study suggests that there is no substantial risk
of acoustic neuroma in the first decade after starting mobile phone use. However, an increase in risk after longer term use or after a
longer lag period could not be ruled out.
British Journal of Cancer (2005) 93, 842–848. doi:10.1038/sj.bjc.6602764 www.bjcancer.com
Published online 30 August 2005
& 2005 Cancer Research UK
Keywords: neuroma, acoustic; telephone; epidemiology; aetiology
                                                          
More than 1 billion people use mobile phones worldwide, with
numbers growing rapidly (NRPB, 2004). There is public concern
about a possible increased risk of brain tumours in mobile phone
users, despite the absence of a known biological mechanism by
which radiofrequency (RF) fields from the phones might cause
neoplasms (IEGMP, 2000; AGNIR, 2003). In contrast to ionising
radiation, RF fields do not have enough energy to break chemical
bonds or damage DNA (AGNIR, 2003).
Acoustic neuroma (vestibular schwannoma) is a nerve sheath
tumour of the vestibulocochlear nerve. This tumour is of particular
interest in relation to mobile phones because brain deposition of
energy from RF fields from a mobile phone is mainly within a
small area of the skull close to the handset, which includes the
vestibular portion of the eighth cranial nerve where acoustic
neuromas develop (Rothman et al, 1996; Dimbylow and Mann,
1999). Some previous epidemiological studies on mobile phone use
have suggested an increased risk of acoustic neuroma (Hardell
et al, 2003; Lo ¨nn et al, 2004), but others have not (Hardell et al,
1999; Inskip et al, 2001; Johansen et al, 2001; Muscat et al, 2002;
Warren et al, 2003; Christensen et al, 2004). The studies to date
have been small (13–159 cases), however, with few long-term users
and wide confidence intervals (CIs).
We undertook six population-based case–control studies within
the Interphone collaboration (Cardis and Kilkenny, 1999) to
investigate the risk of acoustic neuroma in relation to mobile
phone use, with 678 cases and 3553 controls, in the UK and four
Nordic countries. These countries were the first in Western Europe
to introduce mobile phones and to have widespread use of these
devices (Editorial, 1996). They are therefore especially suitable for
the investigation of risks of tumours in relation to long-term
mobile phone use.
MATERIALS AND METHODS
Study design and recruitment
Six population-based case–control studies of acoustic neuroma
aetiology were conducted in the Nordic countries and the UK. The
Received 14 July 2005; revised 27 July 2005; accepted 28 July 2005;
published online 30 August 2005
*Correspondence: MJ Schoemaker; E-mail: Minouk@icr.ac.uk
13From this author onwards in alphabetical order of surname
British Journal of Cancer (2005) 93, 842–848
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yNordic studies were conducted in Denmark nationwide, Finland
excluding Northern Lapland and A ˚land, the Southern and middle
regions of Norway, and the Stockholm, Go ¨teborg and Lund regions
of Sweden. One UK study was conducted in the Thames regions
of Southeast England, and the other in Southern Scotland, the
West Midlands, West Yorkshire and the Trent area. The Danish
and Swedish studies have been reported previously (Christensen
et al, 2004; Lo ¨nn et al, 2004). All studies followed the core protocol
of the Interphone Study, coordinated by the International Agency
for Research on Cancer (Cardis and Kilkenny, 1999) but with
several extensions including a wider age range and hence extra
subjects.
Cases were identified through neurosurgery, neuropathology,
oncology, neurology and otorhinolaryngology centres in the study
areas. Lists of cases were also obtained from the appropriate
population-based cancer registries to ensure completeness of
ascertainment. Eligible cases were individuals diagnosed with
acoustic neuroma between 1 September 1999 and 31 August 2004
(the exact dates within this period vary by centre) at ages 20–69
years in the Nordic countries, 18–59 in Southeast England, and
18–69 in the Northern UK, and resident in the study region at the
time of diagnosis.
Controls in the Nordic centres were randomly selected from the
population register for each study area, frequency matched to
cases on age, sex and region. In the UK, where there is no such
accessible population register, controls were randomly selected
from general practitioners’ practice lists. Controls were subject to
the same age and residence criteria as cases and had never been
diagnosed with a brain tumour.
Subjects were invited by letter to participate in the study. If no
reply was received a repeat letter was sent or the subject was
contacted by telephone. Each study was approved by the
appropriate local ethics committee. Informed consent was
obtained from all subjects at interview.
Data collection
Trained interviewers administered a personal interview, which was
usually conducted at the subject’s home, the hospital or another
place convenient for the subject. For almost half the interviews in
Norway, however, and a small minority elsewhere, where face-to-
face interviews were not possible, interviews were conducted over
the telephone. The interview was computer-assisted, with the
answers being entered directly into the questionnaire program on
a laptop computer, except in Finland, where answers were
recorded on a paper copy of the questionnaire and later entered
into the program.
During the interview, participants were asked about use of
mobile phones, and about models and makes of phones they had
used. Subjects were shown photographs of the phones to aid their
recall of this information.
For each phone model, information was collected on the start
and end date of use, the average amount of time of use and number
of calls. If any substantial changes in use were reported that lasted
for more than 6 months, usage information was also collected for
these periods. Data were collected on mobile phone network
operator, the extent of hands-free use, whether the phone had
mainly been used in rural areas, urban areas or both, the side of
the head on which the phone was mainly used, and whether the
subject was left or right handed.
Statistical analysis
These studies were conducted as part of larger case–control
studies on several types of intracranial tumour, with controls
recruited for the entire set of cases. To increase statistical power,
we used as controls for this analysis all participants interviewed as
controls for the study who fitted the frequency matching strata of
the acoustic neuroma cases.
In the calculation of all exposure indices, except time since first
use, any phone use less than 12 months prior to diagnosis was
excluded because it was most unlikely to be aetiologically relevant.
Time since first use was evaluated up to the diagnosis date. Regular
phone use was defined as having used a mobile phone for at least 6
months more than 1 year prior to diagnosis. As controls were not
individually matched to cases, we constructed a date equivalent to
the cases’ diagnosis date to truncate exposure for controls. We
refer to the date of diagnosis or equivalent date for controls as the
‘reference date’. For controls this was obtained by constructing, for
each centre, case-strata by single calendar year of interview and
single year interval between diagnosis and interview (‘interview lag
time’). Controls interviewed in each calendar year were randomly
allocated to strata of interview lag time, proportionally to the
distribution of the cases in the same calendar year, to obtain a
similar distribution of lag time as in the cases. The reference dates
for controls were then calculated by subtracting the mean
interview lag time in cases in that stratum from the interview
dates of the controls.
We calculated lifetime cumulative numbers of hours of phone
use and numbers of calls by summing the calculated numbers of
hours of use and numbers of calls for each usage pattern of each
phone model. Risks for cumulative use were analysed with and
without modification for reported use of headsets and/or hands-
free sets in a vehicle, using methods described elsewhere
(Christensen et al, 2004; Lo ¨nn et al, 2004).
Analyses were performed by individual centre and on the
overall pooled data set. Odds ratios (ORs) were calculated
as estimates of relative risk, and were obtained using condi-
tional logistic regression, with strata of centre, region, 5-year age
group at reference date and sex, and adjusted for highest
educational level and combinations of interview year and interview
lag time. Heterogeneity in results between centres was assessed
with a log likelihood ratio test comparing a model with an
interaction between centre and the exposure with a model with
only the main effects. We also conducted parallel analyses using a
two-stage random-effects model (Stukel et al, 2001); these are not
presented because they gave very similar results and there was no
between-centre heterogeneity (defining heterogeneity, conserva-
tively, as Po0.10). The statistical package STATA was used
for these analyses (StataCorp, 2003). All statistical tests were
two sided.
We conducted analyses of laterality of the tumour in relation to
the reported side of the head that the phone was predominantly
held, using the methods of Inskip (Inskip et al, 2001) and of
Lo ¨nn et al (2004). The first method assesses the association
between side of phone use and laterality of the tumour in cases
only. In the second method, reported use ipsilateral (or contra-
lateral) to the tumour is analysed in right- and left-sided tumour
cases separately, with 50% of controls randomly assigned to each
group, and the two ORs, with adjustment for confounding factors,
are pooled. As these analyses are dependent on random allocation
of controls, we repeated the random allocation 300 times by
simulation to check for the consistency of reported results, which
were found to be reasonably robust. Subjects who reported using
the phone equally often on each side of the head were treated as
‘exposed’ in both the ipsilateral and contralateral analyses; we also
repeated the analysis excluding this group as a background check
on whether it affected the results. Owing to the potential for the
reported side of phone use to be influenced by recall bias, we also
analysed the relation of tumour laterality to side of handedness,
using the same methods as for reported side of phone use.
As exposure to ionising radiation is a known risk factor for
acoustic neuroma, we repeated the analysis after excluding
subjects who reported having had radiotherapy more than 10
years prior to the reference date.
Mobile phones and acoustic neuroma
MJ Schoemaker et al
843
British Journal of Cancer (2005) 93(7), 842–848 & 2005 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yRESULTS
A total of 827 potential cases and 8460 potential controls were
mailed an invitation letter for the study. The participation rate was
83% (range between centres 69–91%) among cases and 51% (42–
69%) among controls mailed, and 84% (71–93%) and 61% (55–
76%), respectively, based on individuals definitely receiving the
letters. The main reasons for nonparticipation were refusal (cases
9%, controls 28%), inability to contact subjects (cases 2%, controls
18%), no permission from the doctor to approach the subject
(cases 3%, controls 2%) and illness or death (cases 1%, controls
0%). In total, 684 cases were interviewed, of whom six were
excluded because they had neurofibromatosis, leaving 678 cases in
the analysis. The number of controls interviewed was 4340, of
whom 3553 corresponded to matching strata of the cases and were
included in the analysis. The numbers from each centre are shown
in Table 1. In all, 95% of cases and 96% of controls were
interviewed face-to-face, and the remainder over the telephone.
The relative risk of acoustic neuroma for regular mobile phone
use was 0.9 (95% CI: 0.7–1.1) (Table 2). Centre-specific relative
risks for regular phone use were 0.6 (95% CI: 0.3–1.4) for Norway,
0.6 (95% CI: 0.4–1.1) for Finland, 0.8 (95% CI: 0.5–1.3) for
Denmark, 0.9 (95% CI: 0.6–1.4) for Sweden, 1.0 (95% CI: 0.7–1.6)
for Southeast England and 1.1 (95% CI: 0.7–1.6) for the Northern
UK. There was no significant heterogeneity of these relative risks
between centres (P¼0.50), or for any of the other results, so
centre-specific results are not presented, for brevity. Using a 5-year
instead of a 1-year latency period, the relative risk in the pooled
data set was 1.0 (95% CI: 0.8–1.3) (data not shown).
Risk of acoustic neuroma did not increase with increasing time
since first regular phone use or lifetime number of years of use
(Table 2). For first use more than 10 years ago, the relative risk was
1.0 (95% CI: 0.7–1.5) the greatest centre-specific risk, as
previously reported (Lo ¨nn et al, 2004), was in Sweden (OR¼1.6,
95 % CI 0.8–3.4), and nonsignificant relative risks ranged from 0.4
to 1.3 for the other centres (data not shown).
There was no trend in risk with lifetime cumulative hours of
phone use or cumulative number of calls (Table 2). The relative
risk was 1.0 (95% CI: 0.7–1.3) for the top quartile of cumulative
number of calls and 0.9 (95% CI: 0.7–1.2) for the top quartile of
cumulative hours of use compared with never or nonregular users.
Cumulative hours of use 10 years or more prior to the reference
date showed a relative risk of 1.2 (95% CI: 0.8–2.0) for 90 or more
cumulative hours of use (90¼median) compared with never or
nonregular use. Reanalysis of the cumulative exposure estimates
adjusting for use of hands-free devices did not materially alter the
results (data not shown).
Regular use of analogue, or of digital (GSM), phones showed no
association with risk. There was no association with time since first
use, number of years of use or lifetime hours of use for either type
of phone (Table 3). The relative risk for more than 82h
(82¼median) of analogue use in the period 10 or more years
prior to the reference date was 1.5 (95% CI: 0.9–2.5) (data not
shown).
Table 1 Characteristics of acoustic neuroma cases and controls
Cases (n¼678) Controls (n¼3553)
Characteristic N % N %
Sex
Male 318 46.9 1646 46.3
Female 360 53.1 1907 53.7
Age at reference date (years)
18–29 36 5.3 178 5.0
30–39 121 17.9 511 14.4
40–49 171 25.2 880 24.8
50–59 255 37.6 1358 38.2
60–69 95 14.0 626 17.6
Centre
Denmark 102 15.0 782 22.0
Finland 91 13.4 572 16.1
Norway 45 6.6 254 7.2
Sweden 144 21.2 479 13.5
UK-North 133 19.6 892 25.1
UK-Southeast England 163 24.0 574 16.2
Highest school level completed
Primary school 124 18.3 765 21.5
Secondary/high school 195 28.8 992 27.9
Medium level technical/professional 167 24.6 908 25.6
University/higher level technical 190 28.0 882 24.8
Not known 2 0.3 6 0.2
Table 2 Risks of acoustic neuroma in relation to various characteristics
of mobile phone use
Cases Controls
Factor No. % No. % OR (95% CI)
Frequency of use
Never/nonregular use
a 316 46.6 1612 45.4 1.0
Regular use 360 53.1 1934 54.4 0.9 (0.7–1.1)
Not known 2 0.3 7 0.2
Years since first use
Never/nonregular use
a 316 46.6 1612 45.4 1.0
1.5–4
b 174 25.7 1014 28.5 0.8 (0.7–1.0)
5–9 139 20.5 708 19.9 0.9 (0.7–1.2)
X10 47 6.9 212 6.0 1.0 (0.7–1.5)
Not known 2 0.3 7 0.2 P trend¼0.9
Lifetime years of use
Never/nonregular use
a 316 46.6 1612 45.4 1.0
0.5–4 231 34.1 1270 35.7 0.9 (0.7–1.1)
5–9 96 14.2 515 14.5 0.9 (0.7–1.2)
X10 31 4.6 131 3.7 1.1 (0.7–1.8)
Not known 4 0.6 25 0.7 P trend¼0.7
Cumulative no. of calls
c
Never/nonregular use
a 316 46.6 1612 45.4 1.0
o2149 173 25.5 952 26.8 0.9 (0.7–1.1)
2149–8000 82 12.1 473 13.3 0.8 (0.6–1.1)
48000 99 14.6 477 13.4 1.0 (0.7–1.3)
Not known 8 1.2 39 1.1 P trend¼0.5
Cumulative hrs. of use
c
Never/nonregular use
a 316 46.6 1612 45.4 1.0
o116 168 24.8 951 26.8 0.9 (0.7–1.1)
116–534 89 13.1 472 13.3 0.9 (0.7–1.2)
4534 94 13.9 476 13.4 0.9 (0.7–1.2)
Not known 11 1.6 42 1.2 P trend¼0.5
Cumulative hrs. of use by time since first use
Never/nonregular use
a 316 46.6 1612 45.4 1.0
o10 years 313 46.2 1722 48.5 0.9 (0.7–1.1)
X10 years (o90h)
d 19 2.8 106 3.0 0.8 (0.5–1.4)
X10 years (X90h)
d 27 4.0 104 2.9 1.2 (0.8–2.0)
Not known 3 0.4 9 0.3
aNo use or nonregular use defined as user for total of less than 6 months in the
period more than 1 year before the reference date.
bLower limit 1.5 years ago
because regular phone use defined as phone use of at least 6 months’ duration at
least 1 year prior to the reference date.
cClassification based on median and quartiles
among controls who were users: data divided into omedian, medianpthird quartile
and 4third quartile.
d90h is the median number of hours of use 10 or more years
prior to the reference date.
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phone use in regular mobile phone users was 0.9 (95% CI: 0.7–1.1)
using the method described by Lo ¨nn et al (2004) (Table 4). First
use 10 or more years ago showed a relative risk for ipsilateral
tumours of 1.3 (95% CI: 0.8–2.0) and the ipsilateral relative risk
for 10 or more cumulative years of use was 1.8 (95% CI: 1.1–3.1).
Ipsilateral relative risks were not appreciably raised, or were
reduced, for more recent and for shorter periods of use. Relative
risks of contralateral tumours were generally slightly above unity.
Repeating the laterality analyses after excluding subjects reporting
bilateral use gave a near identical result for 10 or more years of
ipsilateral use (OR¼1.8, 95% CI: 1.0–3.3), but a lower relative risk
for 10 or more years of contralateral use (OR¼0.7, 95% CI: 0.3–
1.6) (data not shown). Using the analysis method of Inskip et al
(2001), the overall relative risk of a tumour ipsilateral to use of the
phone was 0.9 (Fisher’s exact test: P¼0.4), the risk 10 or more
years after start of ipsilateral use was 1.5 (P¼0.08), and the risk for
10 or more years of cumulative ipsilateral use was 1.8 (P¼0.09).
The relative risk of a tumour ipsilateral to handedness was 1.0
(95% CI: 0.8–1.3) in regular mobile phone users, and there was
some suggestion of a trend in risk with increasing cumulative years
of use by ipsilateral handed subjects (P trend¼0.09). The relative
risk for 10 or more years of use in these subjects was 1.5 (95% CI:
0.8–2.7) (data not shown).
In total, 89% of cases and 24% of controls responded positively
to the question: ‘Do you suffer from any loss of hearing?’ Cases
reported experiencing hearing loss on average 5.5 years before
diagnosis and controls 13.3 years before the reference date. Among
controls with no hearing loss, 59% of regular phone users reported
predominantly right-sided use, 33% left-sided use and 8% use on
both sides. Among cases, there was a less pronounced preference
of side (49, 40 and 11%, respectively). Reported side of use among
cases was more often contralateral than ipsilateral to the tumour in
short-term phone users and the proportion of cases reporting use
on both sides was highest in long-term users.
Based on the distribution of preferred side of phone use among
controls, if mobile phones cause acoustic neuromas, one might
expect a higher proportion of tumours on the right than on the left
side of the head among regular phone users. The proportion of
right-sided tumours was 53.3% in regular users compared with
49.3% in never or nonregular users (P Fisher’s exact test¼0.34). In
regular analogue phone users, the proportion of right-sided
tumours was 58.8% (P¼0.13) and in regular digital phone users,
it was 52.4% (P¼0.5). However, there was a nonsignificant deficit
of right-sided tumours in long-term phone users overall (48.8%)
and in long-term analogue phone users (48.7%) (data not shown).
Eight cases and 16 controls had had radiotherapy to the skull 10
or more years before the reference date. Excluding these subjects
from the analysis did not materially change the results.
DISCUSSION
There is public anxiety about possible cancer risks from mobile
phone use. Although no such effect has been established to date, if
it existed it would be of significance because of the high prevalence
of use – there are currently more than 1 billion mobile phone users
worldwide (NRPB, 2004). If mobile phones can cause acoustic
neuroma, one would expect an increased risk of acoustic neuroma
in mobile phone users after a certain latency period, and an
Table 3 Risks of acoustic neuroma in relation to various characteristics of analogue or digital phone use
Type of phone
a
Analogue Digital
Factor Cases Controls OR (95% CI) Cases Controls OR (95% CI)
Frequency of use
Never/nonregular use
b 316 1435 1.0 316 1609 1.0
Regular use 101 414 0.9 (0.7–1.2) 323 1770 0.9 (0.7–1.1)
Years since first use
Never/nonregular use
b 316 1435 1.0 316 1609 1.0
1.5–4
c 10 58 0.5 (0.2–1.1) 208 1157 0.9 (0.7–1.1)
5–9 48 195 0.9 (0.6–1.3) 113 598 0.9 (0.7–1.2)
X10 43 161 1.1 (0.7–1.7) 2 15 0.7 (0.2–3.5)
P trend¼0.8 P trend¼0.6
Lifetime years of use
Never/nonregular use
b 316 1435 1.0 316 1609 1.0
0.5–4 71 279 0.9 (0.7–1.3) 264 1413 0.9 (0.7–1.1)
5–9 22 107 0.8 (0.5–1.3) 58 348 0.9 (0.6–1.2)
X10 7 26 1.1 (0.4–2.8) 2 0 (0-)
Not known 1 2 P trend¼0.7 1 7 P trend¼0.5
Cumulative hours of use
d
Never/nonregular use
b 316 1435 1.0 316 1609 1.0
omedian 41 204 0.7 (0.5–1.1) 148 867 0.8 (0.7–1.1)
Median-3rd quartile 21 102 0.7 (0.4–1.2) 80 432 0.9 (0.7–1.2)
43rd quartile 35 102 1.3 (0.8–2.0) 88 434 1.0 (0.7–1.3)
Not known 4 6 P trend¼1.0 7 37 P trend¼0.7
aOf the 5341 phones listed, for 223 (4.2%) the subject did not recall the model and 130 (2.4%) could not be coded to analogue or digital for other reasons. A total of 248
(10.8%) regular users had used one or more phones that could not be categorised. Repeating the analyses without these 248 subjects produced nearly identical results. For the
analogue phone analysis, 260 cases and 1445 controls, and for the digital phone analysis 39 cases and 157 controls were excluded because they were only regular users of all
phones combined or only of the digital or analogue type, respectively. A further one case and 259 controls for the analogue phone analysis and 17 controls for the digital phone
analysis were excluded because they had no controls or cases, respectively, in their matching stratum.
bReference group is never or nonregular use of mobile phones of any type.
cLower limit 1.5 years ago because regular phone use defined as phone use of at least 6 months’ duration at least 1 year prior to the reference date.
dClassification based on the
distribution among controls who were users. Data were divided into o135, 135–493, 4493 for analogue phones, and o94, 94–388, 4388 for digital phones.
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use. Depending on the mechanism, one might expect the risk to be
highest for analogue phone use, because these phones have a
higher average power output than digital phones (IEGMP, 2000)
and because they have been in use the longest. Furthermore,
because the energy from the RF fields is absorbed superficially
close to the handset (Dimbylow and Mann, 1999), the risk should
be highest on the side of the head on which the phone is used.
In our analyses based on several times as many cases and
controls as previously published, from five North European
countries where mobile phones were introduced early, risk of
acoustic neuroma was not raised for regular mobile phone use.
Furthermore, there were no significantly raised risks in relation to
number of years of use, time since first use, cumulative hours of
use or cumulative number of calls, or separately for analogue or
digital phones. There was a significantly raised risk for reported
mobile phone use for 10 or more years ipsilateral to the tumour,
but risks were not raised for shorter durations of ipsilateral use nor
for overall ipsilateral use. Self-reported side of phone use, however,
is potentially an extremely biased variable (Boice and McLaughlin,
2002; Health Council of the Netherlands, 2002; Rothman, 2001),
especially when asked about after development of the tumour.
First, hearing loss produced by the tumour could cause the user
to change use to the other ear, even before the tumour is definitely
diagnosed, leading to an underestimation of ipsilateral risk.
Consistent with this, we found that in short-term users, phone
use by cases was more likely to be contralateral than ipsilateral,
and in long-term users (who would have started phone use before
the tumour first began to develop), reported bilateral phone use
was more common than in short-term users. Secondly, recall bias
could distort the findings in the opposite direction: cases might
over-report ipsilateral use because they believe it caused their
tumour. This bias would be expected not just to raise risks for
ipsilateral use but also to reduce apparent risks for contralateral
use (Rothman, 2001). Contralateral risks were not in general
appreciably reduced in our data, although there was some evidence
of a reduced risk in the analyses of long-term use after excluding
bilateral users. A third potential bias is that the tumour might be
detected earlier in people who use the phone on the same side as
the developing tumour, because they notice the hearing loss sooner
than people who use the phone on the other side. This would result
in increased risks for short-term as well as long-term phone users,
but no increased risk for short-term users was found in our study.
Overall, given the multiple, potentially contrary sources of bias no
firm conclusions can be drawn from the analyses on side of use.
We analysed tumour laterality by handedness as an alternative
marker of actual side of use. Handedness has the advantage that it
is unlikely to be subject to recall bias, but has the disadvantage that
not all people use the phone on their handed side. Risk of acoustic
neuroma ipsilateral to side of handedness was nonsignificantly
raised after 10 or more cumulative years of phone use – compatible
with, but not giving strong support to, the results on reported side
of use.
No trend in risk was found in relation to cumulative hours of
phone use or number of calls. These measures, however, are
subject to substantial misclassification in recall (Parslow et al,
2003), which would dilute any real effect.
Among the eight previously reported studies on risks of acoustic
neuroma and mobile phone use (Hardell et al, 1999, 2003; Inskip
et al, 2001; Johansen et al, 2001; Muscat et al, 2002; Warren et al,
2003; Lo ¨nn et al, 2004; Christensen et al, 2004), two showed any
significant raised risks. A study by Hardell et al (2003) showed a
Table 4 Risks of acoustic neuroma in relation to reported side of use of the mobile phone, by laterality of tumour
Side of tumour compared with reported side of phone use
a
Ipsilateral Contralateral
Factor Cases Controls OR (95% CI) Cases Controls OR (95% CI)
Frequency of use
Reference category
b 457 2444 1.0 446 2497 1.0
Regular use 187 1061 0.9 (0.7–1.1) 198 1008 1.1 (0.9–1.4)
Years since first use
Reference category
b 457 2444 1.0 446 2497 1.0
1.5–4
c 82 557 0.7 (0.5–0.9)
d 103 525 1.2 (0.9–1.5)
5–9 74 380 1.0 (0.7–1.3) 75 378 1.1 (0.8–1.5)
X10 31 124 1.3 (0.8–2.0) 20 105 1.0 (0.6–1.7)
P trend¼0.4 P trend¼0.6
Lifetime years of use
Reference category
b 457 2444 1.0 446 2497 1.0
0.5–4 111 699 0.8 (0.6–1.0)
e 133 654 1.2 (1.0–1.5)
5–9 51 281 0.9 (0.7–1.3) 53 270 1.1 (0.8–1.5)
X10 23 72 1.8 (1.1–3.1)
e 12 73 0.9 (0.5–1.8)
Not known 2 9 P trend¼0.11 11 P trend¼0.9
Cumulative hours of use
f
Reference category
b 457 2444 1.0 446 2497 1.0
omedian 82 522 0.8 (0.6–1.0) 101 497 1.2 (0.9–1.6)
Median-3rd quartile 41 258 0.8 (0.6–1.2) 49 247 1.2 (0.8–1.6)
43rd quartile 60 261 1.2 (0.8–1.6) 42 248 0.9 (0.6–1.3)
Not known 4 20 P trend¼0.5 6 16 P trend¼0.6
aA total of 29 cases excluded because tumour laterality was not known. Five cases and 11 controls excluded because of lack of phone use data. A total of 37 controls excluded
because there were no cases in their matching stratum.
bThe reference category is never or nonregular use of any type of mobile phone and, in the ipsilateral analysis, phone use
only on the opposite side of the tumour, and in the contralateral analysis, phone use only on the same side as the tumour.
cLower limit 1.5 years ago because regular phone use
defined as phone use of at least 6 months’ duration at least 1 year prior to the reference date.
dPo0.01.
ePo0.05.
fClassification based on the distribution among controls who
were users. Data were divided into o119, 119–593 and 4593 for ipsilateral use, and o122, 122–534 and 4534 for contralateral use.
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9.2), which was raised for both ipsilateral and contralateral use.
This is the only study that reported an increased risk in short-term
users, but it has been heavily criticised for methodological
limitations (Rothman, 2000, 2001; Boice and McLaughlin, 2002;
AGNIR, 2003; Ahlbom et al, 2004). The second study (Lo ¨nn et al,
2004), which is part of the present analysis, reported a somewhat
raised risk (OR¼1.9, 95% CI: 0.9–4.1) 10 years after the start of
mobile phone use, which was significantly increased (OR¼3.9,
95% CI: 1.6–9.5) when restricted to tumours ipsilateral to reported
phone use. The results in the present analysis for the Swedish
centre are slightly different from those in the previous publication
because of differences in analytical approach, but are in the same
direction. The six published studies that did not show evidence of
raised risk had few long-term users.
There is potential bias because acoustic neuroma is a very slow
growing tumour (Thomsen and Tos, 1990) and symptoms of the
tumour, in particular hearing loss, experienced long before
diagnosis could have influenced subjects’ behaviours regarding
phone use. This is a plausible reason for the somewhat reduced
relative risk in relation to regular phone use overall, with a relative
risk of 1.0 after excluding phone use during the 5 years prior to
diagnosis.
There is also potential for selection bias among controls. The
overall participation rate among cases was in the range of 83–84%
and among controls was 51–61%, depending on the proportion of
nonrespondents who actually received an invitation. Much effort
was invested to maximise control participation rates by several
rounds of follow-up after the initial invitation letter. To prevent
selection bias, the study was introduced to potential study
participants at some centres as a study about general lifestyle risk
factors for cancer, and at some as a study of the causes of brain
tumours, depending on the local ethics agreements. In the Swedish
and Finnish studies, enquiries to obtain restricted data (over the
telephone) from nonparticipants found a somewhat lower
prevalence of phone use in those willing to give such data than
in full participants (Lo ¨nn et al, 2004; Lahkola et al, 2005), but these
results are of uncertain significance because only a minority of
nonparticipants replied. Generally, however, the lack of raised risk
of acoustic neuroma in relation to phone use overall was seen in
our analyses for centres with higher as well as those with lower
control participation rates.
Confounding by known risks factors is unlikely to explain our
results. Neurofibromatosis type II is associated with the tumour,
but is rare, and we excluded cases with this condition from the
study. High-dose ionising radiation is the only established
environmental risk factor (Ron et al, 1988; Preston et al, 2002),
but results were not altered by excluding patients who received
radiotherapy to the head.
In summary, our findings do not support an increased risk of
acoustic neuroma in the first decade after starting mobile phone
use. For 10 or more years of use, there was an increased risk of
tumours ipsilateral to reported phone use, of uncertain interpreta-
tion. There is no consistent biological evidence that exposure to RF
fields is implicated in the development of tumours nor has a
potential aetiological mechanism been demonstrated (IEGMP,
2000; AGNIR, 2003). Overall, there is no convincing epidemiolo-
gical evidence that RF exposure is related to neoplasia (Ahlbom
et al, 2004). Thus on balance, the evidence suggests that there is no
substantial risk of acoustic neuroma in the first decade of use, but
the possibility of some effect after longer periods remains open.
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